Published in Gene Therapy Weekly, June 9th, 1997
This transaction marks the first investment by Lilly in the field of gene-based therapeutics and the third major corporate collaboration for Megabios. The collaboration will focus on a single selected gene.
Megabios will be responsible for the development of lipid-based gene delivery systems for certain solid tumors and will share responsibility with Lilly for preclinical development. Lilly will be responsible for basic research, worldwide clinical development and regulatory...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.